Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA, a biotechnology company specializing in circular RNA expression systems for advanced gene and cell therapies, has developed its proprietary circVec platform to significantly prolong RNA stability and boost protein production compared with standard mRNA approaches. The platform underpins the company’s ambition to establish a new benchmark for gene expression technologies, while it continues to progress its TG01 immuno‑oncology vaccine candidate for RAS‑mutated cancers via external partnerships and clinical studies in Norway and the U.S.
The company has completed registration of the share capital increase tied to its recent NOK 50 million rights issue and approximately NOK 15 million private placement, including commission shares to pre‑subscribers, with Norway’s business registry. Following a minor upward adjustment in the final share count for the private placement, Circio’s share capital now stands at NOK 126,784,012.20 divided into 211,306,687 shares, with an additional NOK 3.6 million directed share issue pending registration, collectively strengthening its balance sheet to support ongoing R&D and strategic programs.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform enables efficient production of multifunctional circular RNA inside target cells, showing markedly extended RNA half-life and enhanced protein expression versus conventional mRNA-based systems, with potential use across genetic medicine, cell therapy and chronic disease. The company also advances TG01, a peptide vaccine targeting RAS‑mutated cancers, through collaborations in ongoing clinical trials in Norway and the U.S.
Average Trading Volume: 4,042,051
Current Market Cap: NOK208.3M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.